• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background

    Anophthalmia and Microphthalmia Companies

    ID: MRFR/HC/3302-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    Anophthalmia and microphthalmia are rare congenital conditions characterized by the absence or underdevelopment of one or both eyes. Companies involved in the field of genetic disorders, rare diseases, and ophthalmology may contribute to research, development of treatments, and support for individuals affected by these conditions. 

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Anophthalmia and Microphthalmia Market

    Anophthalmia and microphthalmia Market

     


    Latest Anophthalmia and Microphthalmia Companies Updates:


    Santen Pharmaceutical Developing gene therapy for Leber's congenital amaurosis, a rare eye disease with potential applications for other eye conditions.


    Alnylam Pharmaceuticals Leading the way in RNA interference technology, which has potential for treating genetic diseases affecting the eyes.


    Bausch + Lomb A major player in ophthalmic devices, including prosthetics and implants, relevant to Anophthalmia and Microphthalmia patients.


    List of Anophthalmia and Microphthalmia Key companies in the market:



    • Bristol-Myers Squibb Company

    • NUSAPURE

    • ALLERGAN

    • Aerie Pharmaceuticals, Inc.

    • Pfizer Inc.

    • Valeant Pharmaceuticals International, Inc.

    • Bayer AG

    • Genentech, Inc.

    • Novartis AG 

    • Regeneron Pharmaceuticals, Inc.

    • Shire,

    • Santen Pharmaceutical Co., Ltd.